RxDoctor Payments Data

Erica Garcia Tovar, APRN

Family · Sebring, FLNPI 1750935524

Payments from drug & device makers

$1,252in general payments, 2019–2025

Across 57 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$255
  • Corcept Therapeutics$192
  • Amgen$159
  • Novo Nordisk$108
  • AstraZeneca$83
  • Novartis$81
  • plus $374 from 9 others

What the payments were for

  • Food & beverage$1,252100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,252 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$163,181
Medicare patients
529
Services billed
3,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$41,722
TrulicityDulaglutide11$29,640
MounjaroTirzepatide24$29,461
JardianceEmpagliflozin23$26,676
OzempicSemaglutide26$26,435
XareltoRivaroxaban12$18,749
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,487
Rosuvastatin Calcium212$3,755
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,658
Levothyroxine Sodium223$2,713
Omeprazole142$2,521
Gabapentin95$1,738
Atorvastatin Calcium284$1,629
PaxlovidNirmatrelvir/Ritonavir13$1,347
Esomeprazole Magnesium11$1,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$67$59,10135 claims
PfizerEliquis, Paxlovid$61$43,06950 claims
Novo NordiskOzempic$108$26,43526 claims
GSKAnoro Ellipta$13$10,48714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Sebring

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →